Recently, AML harboring a panel of nine mutations encompassing the eight sAML-type mutations and RUNX1 mutation have been categorized as AML with myelodysplasia-related (MDS-R) gene mutations in the 2022 International Consensus Classification (ICC) [9], and the adverse-risk group in the 2022 ELN risk classification [10]. The gene discussed is RUNX1; the disease is acute myeloid leukemia.